Simris Biologics collaborates with leading academic and clinical institutions, contract development and manufacturing organisations (CDMO), chemicals companies and pharmaceutical companies worldwide. Collaboration agreements and license agreements play a central role in the Company’s commercial strategy.
Within collaboration agreements Simris Biologics generates revenue for R&D services and materials provided to a partner developing a product. This could be a chemicals company looking to develop a new pesticide, a cosmetics brand seeking novel natural compounds with anti-aging properties or pharmaceutical companies aiming to develop a new Antibody Drug Conjugate (ADC) to treat cancer patients. Further revenue from the collaboration is generated as a project reaches key development milestones, gains regulatory approval in given territories and for products that reach commercial use, royalties on sales throughout the life of our patents.
License agreements provide a partner, such as a pharmaceutical company, the right to reserve a novel, natural biologic towards a specific target for an agreed length of time.
Interested in our technology?
Please contact our business development team directly if you would be interested to learn more about our novel products library and to discuss a possible collaboration.
- ADC payloads
- Cyano Standards
- Cyano Reagents